TN2011000553A1 - Fgf21 mutants and uses thereof - Google Patents

Fgf21 mutants and uses thereof

Info

Publication number
TN2011000553A1
TN2011000553A1 TNP2011000553A TN2011000553A TN2011000553A1 TN 2011000553 A1 TN2011000553 A1 TN 2011000553A1 TN P2011000553 A TNP2011000553 A TN P2011000553A TN 2011000553 A TN2011000553 A TN 2011000553A TN 2011000553 A1 TN2011000553 A1 TN 2011000553A1
Authority
TN
Tunisia
Prior art keywords
fgf21 mutant
polypeptides
fgf21 mutants
mutant polypeptides
pharmaceutical compositions
Prior art date
Application number
TNP2011000553A
Inventor
Edward John Belouski
Mureille Marie Ellison
Agnes Eva Hamburger
Randy Ira Hecht
Yue Sheng Li
Mark Leo Michaels
Jeonghoon Sun
Jing Xu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/033478 external-priority patent/WO2010129503A1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of TN2011000553A1 publication Critical patent/TN2011000553A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
TNP2011000553A 2009-05-05 2011-10-31 Fgf21 mutants and uses thereof TN2011000553A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17573609P 2009-05-05 2009-05-05
PCT/US2010/033478 WO2010129503A1 (en) 2009-05-05 2010-05-04 Fgf21 mutants and uses thereof

Publications (1)

Publication Number Publication Date
TN2011000553A1 true TN2011000553A1 (en) 2013-05-24

Family

ID=52988550

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2011000553A TN2011000553A1 (en) 2009-05-05 2011-10-31 Fgf21 mutants and uses thereof

Country Status (3)

Country Link
AR (1) AR108568A2 (en)
TN (1) TN2011000553A1 (en)
UA (1) UA107458C2 (en)

Also Published As

Publication number Publication date
AR108568A2 (en) 2018-09-05
UA107458C2 (en) 2015-01-12

Similar Documents

Publication Publication Date Title
PH12015502433A1 (en) Fgf21 mutants and uses thereof
TN2011000161A1 (en) Fgf21 mutants and uses thereof
MY152721A (en) Fgf21 mutants and uses thereof
WO2010129600A3 (en) Fgf21 mutants and uses thereof
MX2011013903A (en) Chimeric fgf19 polypeptides and uses thereof.
MX2009002816A (en) Albumin fusion proteins.
PH12013501101A1 (en) Immunosuppressive polypeptides and nucleic acids
UA105073C2 (en) Anti-fractalkine antibody, composition and method for treating inflammatory disorders
AP2011005814A0 (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases.
MX340807B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
TN2011000553A1 (en) Fgf21 mutants and uses thereof
UA102395C2 (en) Fgf21 mutants and use thereof
TN2010000563A1 (en) Fgf 21 mutants and uses thereof
WO2008033374A3 (en) Ocl-2a3 compositions and uses thereof
EP2582379A4 (en) Compositions and methods for the treatment of atherosclerosis